- Home
- TACH vs EOLS Comparison
TACH vs EOLS Comparison
Compare TACH & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TACH
- EOLS
- Stock Information
- Founded
- TACH 2024
- EOLS 2012
- Country
- TACH United States
- EOLS United States
- Employees
- TACH N/A
- EOLS N/A
- Industry
- TACH
- EOLS Biotechnology: Pharmaceutical Preparations
- Sector
- TACH
- EOLS Health Care
- Exchange
- TACH Nasdaq
- EOLS Nasdaq
- Market Cap
- TACH 349.1M
- EOLS 406.9M
- IPO Year
- TACH 2025
- EOLS 2018
- Fundamental
- Price
- TACH $10.15
- EOLS $6.25
- Analyst Decision
- TACH
- EOLS Strong Buy
- Analyst Count
- TACH 0
- EOLS 4
- Target Price
- TACH N/A
- EOLS $21.25
- AVG Volume (30 Days)
- TACH 92.7K
- EOLS 1.1M
- Earning Date
- TACH 01-01-0001
- EOLS 11-05-2025
- Dividend Yield
- TACH N/A
- EOLS N/A
- EPS Growth
- TACH N/A
- EOLS N/A
- EPS
- TACH 0.19
- EOLS N/A
- Revenue
- TACH N/A
- EOLS $277,941,000.00
- Revenue This Year
- TACH N/A
- EOLS $13.68
- Revenue Next Year
- TACH N/A
- EOLS $27.96
- P/E Ratio
- TACH $53.19
- EOLS N/A
- Revenue Growth
- TACH N/A
- EOLS 17.15
- 52 Week Low
- TACH $10.00
- EOLS $5.71
- 52 Week High
- TACH $10.38
- EOLS $17.82
- Technical
- Relative Strength Index (RSI)
- TACH N/A
- EOLS 40.98
- Support Level
- TACH N/A
- EOLS $6.08
- Resistance Level
- TACH N/A
- EOLS $6.55
- Average True Range (ATR)
- TACH 0.00
- EOLS 0.21
- MACD
- TACH 0.00
- EOLS 0.06
- Stochastic Oscillator
- TACH 0.00
- EOLS 67.53
About TACH Titan Acquisition Corp. Class A Ordinary Shares
Titan Acquisition Corp is a blank check company.
About EOLS Evolus Inc.
Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.